Etonogestrel
Eluryng, Enilloring, Ethinyl Estradiol / Etonogestrel, Haloette, Nexplanon, Nuvaring (etonogestrel) is a small molecule pharmaceutical. Etonogestrel was first approved as Nuvaring on 2001-10-03.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Nexplanon (discontinued: Nexplanon)
CombinationsEluryng, Enilloring, Ethinyl estradiol; etonogestrel, Haloette, Nuvaring (discontinued: Veraring)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| eluryng | ANDA | 2025-01-15 |
| enilloring | ANDA | 2024-06-24 |
| etonogestrel and ethinyl estradiol | ANDA | 2022-09-30 |
| etonogestrel and ethinyl estradiol vaginal | ANDA | 2024-07-08 |
| etonogestrel and ethinyl estradiol vaginal ring | ANDA | 2024-06-24 |
| etonogestrel/ethinyl estradiol | NDA authorized generic | 2025-02-26 |
| haloette | ANDA | 2024-04-19 |
| nexplanon | New Drug Application | 2024-12-13 |
| nuvaring | New Drug Application | 2025-03-21 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Clinical
Clinical Trials
138 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | — | — | 7 | 7 | 10 | 25 | 28 | 76 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 2 | 2 | 7 | 3 | 14 |
| Uterine hemorrhage | D014592 | — | — | 1 | 5 | — | 4 | 1 | 10 |
| Contraception behavior | D003268 | — | — | 1 | — | 1 | 2 | 5 | 9 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 2 | — | 3 | 3 | 8 |
| Hiv | D006678 | — | O98.7 | — | 1 | — | 3 | 3 | 7 |
| Drug interactions | D004347 | — | — | — | — | — | 3 | 2 | 5 |
| Emergencies | D004630 | — | — | — | — | — | 3 | 2 | 5 |
| Menstruation disturbances | D008599 | — | N91.5 | — | — | — | 2 | 2 | 4 |
| Metrorrhagia | D008796 | — | N92.1 | — | — | — | 2 | 1 | 3 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dysmenorrhea | D004412 | — | N94.6 | — | 2 | 2 | — | — | 4 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hyperplasia | D006965 | EFO_0000536 | — | — | 1 | — | — | 1 | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | — | — | — | 2 | 3 |
| Pregnancy rate | D018873 | — | — | 1 | — | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hormonal contraception | D000080282 | — | — | — | — | — | — | 2 | 2 |
| Body weight | D001835 | EFO_0004338 | — | — | — | — | — | 2 | 2 |
| Weight loss | D015431 | — | — | — | — | — | — | 2 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Microbiota | D064307 | — | — | — | — | — | — | 1 | 1 |
| Opioid-related disorders | D009293 | EFO_0005611 | F11 | — | — | — | — | 1 | 1 |
| Sexual behavior | D012725 | — | — | — | — | — | — | 1 | 1 |
| Sexually transmitted diseases | D012749 | — | A50-A64 | — | — | — | — | 1 | 1 |
| Body weight changes | D001836 | — | — | — | — | — | — | 1 | 1 |
| Weights and measures | D014894 | — | — | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Etonogestrel |
| INN | etonogestrel |
| Description | Etonogestrel is a medication which is used as a means of birth control for women. It is available as an implant placed under the skin of the upper arm under the brand names Nexplanon and Implanon. It is a progestin that is also used in combination with ethinylestradiol, an estrogen, as a vaginal ring under the brand names NuvaRing and Circlet. Etonogestrel is effective as a means of birth control and lasts at least three or four years with some data showing effectiveness for five years. Following removal, fertility quickly returns.
|
| Classification | Small molecule |
| Drug class | estrogens; progestins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC |
Identifiers
| PDB | — |
| CAS-ID | 54048-10-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1531 |
| ChEBI ID | 50777 |
| PubChem CID | 21729469 |
| DrugBank | DB00294 |
| UNII ID | 304GTH6RNH (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Nuvaring – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Nuvaring – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Nexplanon – Organon
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Nexplanon – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Etonogestrel
+
Ethinyl estradiol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Etonogestrel
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,582 documents
View more details
Safety
Black-box Warning
Black-box warning for: Eluryng, Enilloring, Etonogestrel and ethinyl estradiol, Etonogestrel and ethinyl estradiol vaginal, Etonogestrel and ethinyl estradiol vaginal ring, Etonogestrel/ethinyl estradiol, Haloette, Nuvaring
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
67,321 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use